Luci-eASCs were defined according to the criteria of the International Society for Cellular Therapy [36 (link)]. Luci-eASCs were stained using antibodies for CD73 (AD2), CD90 (5E10, both from Becton Dickinson), CD105 (43A3, Biolegend, San Diego, CA, USA), CD14 (RM052, Immunotech, Monrovia, CA, USA), CD34 (8G12, Becton Dickinson, Franklin Lakes, NJ, USA), CD45 (J33, Beckman Coulter, Brea, CA, USA) and HLA-DR (AF6-120.1, eBiosciences, Waltham, MA, USA) [18 (link)].
Free full text: Click here